

15. A compound chosen from:  
 [1R-[1 $\alpha$ ,2 $\alpha$ ,3 $\beta$ (1R\*,2S\*),5 $\beta$ ]]-3-[7-[[2-(4-Fluorophenyl)cyclopropyl]amino]-5-[(3,3,3-trifluoropropylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol;  
 [1R-[1 $\alpha$ ,2 $\alpha$ ,3 $\beta$ (1R\*,2S\*),5 $\beta$ ]]-3-[7-[[2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-[(3,3,3-trifluoropropylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol;  
 [1S-[1 $\alpha$ ,2 $\alpha$ ,3 $\beta$ (1S\*,2R\*),5 $\beta$ ]]-3-[7-[[2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-cyclopentane-1,2-diol;  
 1R-[1 $\alpha$ ,2 $\alpha$ ,3 $\beta$ (1R\*,2S\*)5 $\beta$ ]]-3-[5-(Butylthio)-7-[[2-(3,4-difluorophenyl)cyclopropyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol;  
 [1S-[1 $\alpha$ ,2 $\beta$ ,3 $\beta$ ,4 $\alpha$ (1S\*,2R\*)]]-4-[5-(Butylthio)-7-[[2-(4-fluorophenyl)cyclopropyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2,3-triol; and  
 pharmaceutically acceptable salts and solvates thereof, and  
 solvates of such salts.
16. A compound chosen from:  
 [1R-[1 $\alpha$ ,2 $\alpha$ ,3 $\beta$ (1R\*,2S\*),5 $\beta$ ]]-3-[7-[[2-(4-Fluorophenyl)cyclopropyl]amino]-5-[(3,3,3-trifluoropropylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol;  
 [1R-[1 $\alpha$ ,2 $\alpha$ ,3 $\beta$ (1R\*,2S\*),5 $\beta$ ]]-3-[7-[[2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-[(3,3,3-trifluoropropylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol;  
 [1S-[1 $\alpha$ ,2 $\alpha$ ,3 $\beta$ (1S\*,2R\*),5 $\beta$ ]]-3-[7-[[2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-cyclopentane-1,2-diol;  
 1R-[1 $\alpha$ ,2 $\alpha$ ,3 $\beta$ (1R\*,2S\*),5 $\beta$ ]]-3-[5-(Butylthio)-7-[[2-(3,4-difluorophenyl)cyclopropyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol; and  
 [1S-[1 $\alpha$ ,2 $\beta$ ,3 $\beta$ ,4 $\alpha$ (1S\*,2R\*)]]-4-[5-(Butylthio)-7-[[2-(4-fluorophenyl)cyclopropyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2,3-triol.
17. A compound chosen from:  
 [1R-[1 $\alpha$ ,2 $\alpha$ ,3 $\beta$ (1R\*,2S\*),5 $\beta$ ]]-3-[7-[[2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-[(3,3,3-trifluoropropyl

- thio]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol;  
 [1S-[1 $\alpha$ ,2 $\alpha$ ,3 $\beta$ (1S\*,2R\*),5 $\beta$ ]]-3-[7-[[2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-cyclopentane-1,2-diol; and  
 pharmaceutically acceptable salts and solvates thereof, and  
 solvates of such salts.
18. A compound chosen from:  
 [1R-[1 $\alpha$ ,2 $\alpha$ ,3 $\beta$ (1R\*,2S\*)5 $\beta$ ]]-3-[7-[[2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-[(3,3,3-trifluoropropylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol; and  
 [1S-[1 $\alpha$ ,2 $\alpha$ ,3 $\beta$ (1S\*,2R\*),5 $\beta$ ]]-3-[7-[[2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-cyclopentane-1,2-diol.
19. An oral pharmaceutical composition comprising  
 [1S-[1 $\alpha$ ,2 $\alpha$ ,3 $\beta$ (1S\*,2R\*),5 $\beta$ ]]-3-[7-[[2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-cyclopentane-1,2-diol in combination with  
 a pharmaceutically acceptable diluent, adjuvant, and/or carrier suitable for oral administration,  
 wherein said oral pharmaceutical composition is in the form of a tablet, pill, capsule, liquid, powder, or granule.
20. The oral pharmaceutical composition according to claim 19, wherein said oral pharmaceutical composition is in the form of a tablet.
21. The oral pharmaceutical composition according to claim 19, wherein said liquid is a syrup or suspension.
22. A method of treatment of post-myocardial infarction which comprises orally administering to a patient suffering therefrom a therapeutically effective amount of [1S-[1 $\alpha$ ,2 $\alpha$ ,3 $\beta$ (1S\*,2R\*),5 $\beta$ ]]-3-[7-[[2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-cyclopentane-1,2-diol.
23. A method of treatment of stroke which comprises orally administering to a person suffering therefrom a therapeutically effective amount of [1S-[1 $\alpha$ ,2 $\alpha$ ,3 $\beta$ (1S\*,2R\*),5 $\beta$ ]]-3-[7-[[2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-cyclopentane-1,2-diol.

\* \* \* \* \*